Reading a pamphlet in the doctor’s office about which vaccines to get may help nudge older adults to get vaccinated.

Larson Financial Group LLC cut its holdings in GSK plc (NYSE:GSK – Free Report) by 52.7% during the fourth quarter, according ...

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure ...

Bank of New York Mellon Corp grew its position in GSK plc (NYSE:GSK – Free Report) by 2.2% during the fourth quarter, ...

Dr. Kruger is an expert in cancer biology and epigenetics, having led research and development at GlaxoSmithKline (GSK) and biotechnology corporations. Dr. Knight worked at GSK for over 25 years ...

UK initiative to harness big biological data sets and look deeper into how the human body works and malfunctions ...

The company’s two established vaccines continue to boost sales for GSK’s greater vaccine portfolio, with Bexsero crossing the $1 billion milestone in 2024 and Menveo adding 387 million euros ...

GSK already scores pretty well among the top 14 pharma companies when it comes to R&D efficiency – ranking third behind Pfizer and Novartis in an analysis of R&D productivity published last year ...

GSK Pharma had reported a consolidated net profit ... scale-up of vaccine business and enhanced efforts to boost vaccine prospects. The brokerage kept a 'neutral' rating on the stock, with a ...

GSK’s Arepanrix H5N1 A/American wigeon clade ... laid out $121.4 million to boost national inventories of CSL Seqirus’ MF59 adjuvant, which is used in some bird flu vaccines to beef up the ...

enhanced efforts to boost vaccine prospects. The brokerage valued GSK Pharma at a target price of Rs 2,170. For the quarter ended December, of the current fiscal year 2025, the company's revenue ...

That said, while sales of HIV and cancer treatments are strong, GSK’s late-stage pipeline of new drugs and vaccines needs a boost. Also, the firm faces an ‘earnings cliff’ three years from ...